The Impact of Obesity on the Outcomes of Adult Patients with Acute Lymphoblastic Leukemia – A Single Center Retrospective Study

References

• Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012;157:463–471. doi:10.1111/j.1365-2141.2012.09095.x
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Walewski J, Dohner H, et al. Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial. Blood. 2014;124:3870–3879. doi:10.1182/blood-2014-03-563627
   PubMed Web of Science ®Google Scholar
• Thomas DA, O’Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome–negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28:3880–3889. doi:10.1200/JCO.2009.26.9456
   PubMed Web of Science ®Google Scholar
• Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances longterm outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014;123:843–850. doi:10.1182/blood-2013-09-529008
   PubMed Web of Science ®Google Scholar
• Jain P, Kantarjian H, Ravandi F, et al. The combination of hyper- CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience. Leukemia. 2014;28:973–975.
   PubMed Web of Science ®Google Scholar
• Giebel S, Krawczyk-Kulis M, Kyrcz-Krzemien S, et al. Could cytogenetics and minimal residual disease replace conventional risk criteria in adults with Ph-negative acute lymphoblastic leukaemia? Br J Haematol. 2009;144:970–972.
   Web of Science ®Google Scholar
• Van Dongen JJ, van der Velden VH, et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125:3996–4009. doi:10.1182/blood-2015-03-580027
   PubMed Web of Science ®Google Scholar
• Butturini AM, Dorey FJ, Lange BJ, et al. Obesity and outcome in pediatric acute lymphoblastic leukemia. J Clin Oncol. 2007;25:2063–2069. doi:10.1200/JCO.2006.07.7792
   PubMed Web of Science ®Google Scholar
• Heiblig M, Elhamri M, Nicolini FE, et al. Effect of initial body mass index on survival outcome of patients with acute leukemia: a single-center retrospective study. Clin Lymphoma Myeloma Leuk. 2015;15(Suppl):S7–13. doi:10.1016/j.clml.2015.02.005
   Web of Science ®Google Scholar
• Ramanujachar R, Richards S, Hann I, et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer. 2007;48(3):254–261. doi:10.1002/pbc.20749
   PubMed Web of Science ®Google Scholar
• Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood. 1998;92(5):1556–1564.
   PubMed Web of Science ®Google Scholar
• Rytting ME, Jabbour EJ, O’Brien SM, et al. Acute lymphoblastic leukemia in adolescents and young adults. Cancer. 2017;123(13):2398–2403. doi:10.1002/cncr.30624
   Web of Science ®Google Scholar
• Fleming NGM, Robinson T, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384:766–781. doi:10.1038/leu.2013.312
   Web of Science ®Google Scholar
• Ogden CL, Carrol MD, Kit BK, et al. Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA. 2014;311:806. doi:10.1001/jama.2014.732
   PubMed Web of Science ®Google Scholar
• De Pergola G, Silvestris F. Obesity as a major risk factor for cancer. J Obes. 2013;23:1–10. doi:10.1155/2013/291546
   Google Scholar
• Butturini A, Vignetti M, Gubbiotti S, et al. Obesity independently affects event free survival (EFS) in adults with BCR-ABL-negative acute lymphoblastic leukemia (ALL): a retrospective analysis of two GIMEMA studies. Blood. 2005;106 Abstract 520a.
   Web of Science ®Google Scholar
• Hijiya N, Panetta JC, Zhou Y, et al. Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood. 2006;108:3997–4002. doi:10.1182/blood-2006-05-024414
   PubMed Web of Science ®Google Scholar
• Medeiros BC, Othus M, Estey EH, et al. Impact of body-mass index in the outcome of adult patients with acute myeloid leukemia. Haematologica. 2012;97:1401–1404. doi:10.3324/haematol.2011.056390
   PubMed Web of Science ®Google Scholar
• Lee HJ, Licht AS, Hyland AJ, et al. Is obesity a prognostic factor for acute myeloid leukemia outcome? Ann Hematol. 2012;91:359–365. doi:10.1007/s00277-011-1319-8
   PubMed Web of Science ®Google Scholar
• Estey E, Thall P, Kantarjian H, et al. Association between increased body mass index and a diagnosis of acute promyelocytic leukemia in patients with acute myeloid leukemia. Leukemia. 1997;11:1661–1664. doi:10.1038/sj.leu.2400783
   PubMed Web of Science ®Google Scholar
• Breccia M, Mazzarella L, Bagnardi V, et al. Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. Blood. 2012;119:49–54. doi:10.1182/blood-2011-07-369595
   PubMed Web of Science ®Google Scholar
• Castillo JJ, Mulkey F, Geyer S, et al. Relationship between obesity and clinical outcome in adults with acute myeloid leukemia: a pooled analysis from four CALGB (alliance) clinical trials. Am J Hematol. 2016;91:199–204. doi:10.1002/ajh.24230
   PubMed Web of Science ®Google Scholar
• Warner JT, Cowan FJ, Dunstan FD, et al. The validity of body mass index for the assessment of adiposity in children with disease states. Ann Hum Biol. 1997;24:209–215. doi:10.1080/03014469700004942
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer FX. Obesity: criteria and classification. Proc Nutr Soc. 2000;59:505–509. doi:10.1017/S0029665100000732
   PubMed Web of Science ®Google Scholar
• Farr OM, Gavrieli A, Mantzoros CS. Leptin applications in 2015: what have we learned about leptin and obesity? Curr Opin Endocrinol Diabetes Obes. 2015;22:353–359. doi:10.1097/MED.0000000000000184
   PubMedGoogle Scholar
• Aref S, Ibrahim L, Azmy E, Al Ashary R. Impact of serum adiponectin and leptin levels in acute leukemia. Hematology. 2013;18:198–203. doi:10.1179/1607845412Y.0000000059
   PubMed Web of Science ®Google Scholar
• Han TJ, Wang X. Leptin and its receptor in hematologic malignancies. Int J Clin Exp Med. 2015;8:19840–19849.
   PubMed Web of Science ®Google Scholar
• Wex H, Ponelis E, Wex T, et al. Plasma leptin and leptin receptor expression in childhood acute lymphoblastic leukemia. Int J Hematol. 2002;76:446–452. doi:10.1007/BF02982810
   PubMed Web of Science ®Google Scholar
• Mouzaki A, Panagoulias I, Dervilli Z, et al. Expression patterns of leptin receptor (OB-R) isoforms and direct in vitro effects of recombinant leptin on OB-R, leptin expression and cytokine secretion by human hematopoietic malignant cells. Cytokine. 2009;48:203–211. doi:10.1016/j.cyto.2009.07.006
   PubMed Web of Science ®Google Scholar
• Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol. 1988;6:1321–1327. doi:10.1200/JCO.1988.6.8.1321
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Wolff AC, Mathijssen RH, et al. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese. J Clin Oncol. 2007;25:4707–4713. doi:10.1200/JCO.2007.11.2938
   PubMed Web of Science ®Google Scholar